JP7138077B2 - 卵巣がん及び／又は子宮がんのリスクを判定する方法 - Google Patents
卵巣がん及び／又は子宮がんのリスクを判定する方法 Download PDFInfo
- Publication number
- JP7138077B2 JP7138077B2 JP2019081618A JP2019081618A JP7138077B2 JP 7138077 B2 JP7138077 B2 JP 7138077B2 JP 2019081618 A JP2019081618 A JP 2019081618A JP 2019081618 A JP2019081618 A JP 2019081618A JP 7138077 B2 JP7138077 B2 JP 7138077B2
- Authority
- JP
- Japan
- Prior art keywords
- snp
- genotype
- disease
- risk
- model
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 238000000034 method Methods 0.000 title claims description 33
- 206010033128 Ovarian cancer Diseases 0.000 title claims description 9
- 206010061535 Ovarian neoplasm Diseases 0.000 title claims description 9
- 208000002495 Uterine Neoplasms Diseases 0.000 title claims description 8
- 206010046766 uterine cancer Diseases 0.000 title claims description 8
- 230000002611 ovarian Effects 0.000 title 1
- 239000002773 nucleotide Substances 0.000 claims description 22
- 125000003729 nucleotide group Chemical group 0.000 claims description 22
- 230000002596 correlated effect Effects 0.000 claims description 5
- 206010028980 Neoplasm Diseases 0.000 claims description 3
- 201000011510 cancer Diseases 0.000 claims description 3
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 2
- 210000001124 body fluid Anatomy 0.000 claims description 2
- 239000010839 body fluid Substances 0.000 claims description 2
- 210000004291 uterus Anatomy 0.000 claims description 2
- 201000010099 disease Diseases 0.000 description 89
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 89
- 230000000052 comparative effect Effects 0.000 description 22
- 210000000349 chromosome Anatomy 0.000 description 20
- 239000000523 sample Substances 0.000 description 12
- 238000006243 chemical reaction Methods 0.000 description 11
- 108020004414 DNA Proteins 0.000 description 10
- 238000007477 logistic regression Methods 0.000 description 8
- 238000003752 polymerase chain reaction Methods 0.000 description 7
- 239000013611 chromosomal DNA Substances 0.000 description 6
- UYTPUPDQBNUYGX-UHFFFAOYSA-N guanine Chemical compound O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- 238000000018 DNA microarray Methods 0.000 description 5
- 241000282412 Homo Species 0.000 description 5
- 230000003321 amplification Effects 0.000 description 5
- 230000000875 corresponding effect Effects 0.000 description 5
- 239000012634 fragment Substances 0.000 description 5
- 238000003199 nucleic acid amplification method Methods 0.000 description 5
- 102000054765 polymorphisms of proteins Human genes 0.000 description 5
- 238000004458 analytical method Methods 0.000 description 4
- 238000001514 detection method Methods 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 238000009396 hybridization Methods 0.000 description 4
- 230000013011 mating Effects 0.000 description 4
- 102000053602 DNA Human genes 0.000 description 3
- 238000012300 Sequence Analysis Methods 0.000 description 3
- 108020004682 Single-Stranded DNA Proteins 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 230000001747 exhibiting effect Effects 0.000 description 3
- 108091008146 restriction endonucleases Proteins 0.000 description 3
- 210000003296 saliva Anatomy 0.000 description 3
- 229930024421 Adenine Natural products 0.000 description 2
- GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Chemical compound NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 description 2
- 238000000585 Mann–Whitney U test Methods 0.000 description 2
- 210000001766 X chromosome Anatomy 0.000 description 2
- 229960000643 adenine Drugs 0.000 description 2
- 238000013528 artificial neural network Methods 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 238000013527 convolutional neural network Methods 0.000 description 2
- OPTASPLRGRRNAP-UHFFFAOYSA-N cytosine Chemical compound NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 238000010801 machine learning Methods 0.000 description 2
- 108020004707 nucleic acids Proteins 0.000 description 2
- 102000039446 nucleic acids Human genes 0.000 description 2
- 150000007523 nucleic acids Chemical group 0.000 description 2
- 238000007894 restriction fragment length polymorphism technique Methods 0.000 description 2
- RWQNBRDOKXIBIV-UHFFFAOYSA-N thymine Chemical group CC1=CNC(=O)NC1=O RWQNBRDOKXIBIV-UHFFFAOYSA-N 0.000 description 2
- 230000009466 transformation Effects 0.000 description 2
- 238000000844 transformation Methods 0.000 description 2
- 238000010200 validation analysis Methods 0.000 description 2
- UCTWMZQNUQWSLP-VIFPVBQESA-N (R)-adrenaline Chemical compound CNC[C@H](O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-VIFPVBQESA-N 0.000 description 1
- 229930182837 (R)-adrenaline Natural products 0.000 description 1
- 208000034826 Genetic Predisposition to Disease Diseases 0.000 description 1
- 206010071602 Genetic polymorphism Diseases 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- 238000007397 LAMP assay Methods 0.000 description 1
- 108020005187 Oligonucleotide Probes Proteins 0.000 description 1
- 206010033645 Pancreatitis Diseases 0.000 description 1
- 208000024313 Testicular Neoplasms Diseases 0.000 description 1
- 206010057644 Testis cancer Diseases 0.000 description 1
- 230000023555 blood coagulation Effects 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000002790 cross-validation Methods 0.000 description 1
- 229940104302 cytosine Drugs 0.000 description 1
- 230000035487 diastolic blood pressure Effects 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 229960005139 epinephrine Drugs 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 238000012252 genetic analysis Methods 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 206010021093 hypospadias Diseases 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000010365 information processing Effects 0.000 description 1
- 210000002200 mouth mucosa Anatomy 0.000 description 1
- 239000002751 oligonucleotide probe Substances 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 238000000306 qrs interval Methods 0.000 description 1
- 238000007637 random forest analysis Methods 0.000 description 1
- 230000000306 recurrent effect Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000000611 regression analysis Methods 0.000 description 1
- 238000012502 risk assessment Methods 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 210000003765 sex chromosome Anatomy 0.000 description 1
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 1
- 238000013179 statistical model Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 238000012706 support-vector machine Methods 0.000 description 1
- 201000003120 testicular cancer Diseases 0.000 description 1
- 229940113082 thymine Drugs 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
Images
Landscapes
- Investigating Or Analysing Biological Materials (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2019081618A JP7138077B2 (ja) | 2019-04-23 | 2019-04-23 | 卵巣がん及び／又は子宮がんのリスクを判定する方法 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2019081618A JP7138077B2 (ja) | 2019-04-23 | 2019-04-23 | 卵巣がん及び／又は子宮がんのリスクを判定する方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020178535A JP2020178535A (ja) | 2020-11-05 |
| JP2020178535A5 JP2020178535A5 (enrdf_load_stackoverflow) | 2022-03-15 |
| JP7138077B2 true JP7138077B2 (ja) | 2022-09-15 |
Family
ID=73022522
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019081618A Active JP7138077B2 (ja) | 2019-04-23 | 2019-04-23 | 卵巣がん及び／又は子宮がんのリスクを判定する方法 |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JP7138077B2 (enrdf_load_stackoverflow) |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2007086526A1 (ja) | 2006-01-27 | 2007-08-02 | National University Corporation Kanazawa University | 遺伝子多型およびその用途 |
| JP2012531210A (ja) | 2009-06-25 | 2012-12-10 | イェール ユニバ−シティ− | Ｂｒｃａ１における一塩基多型および癌のリスク |
-
2019
- 2019-04-23 JP JP2019081618A patent/JP7138077B2/ja active Active
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2007086526A1 (ja) | 2006-01-27 | 2007-08-02 | National University Corporation Kanazawa University | 遺伝子多型およびその用途 |
| JP2012531210A (ja) | 2009-06-25 | 2012-12-10 | イェール ユニバ−シティ− | Ｂｒｃａ１における一塩基多型および癌のリスク |
Also Published As
| Publication number | Publication date |
|---|---|
| JP2020178535A (ja) | 2020-11-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7165099B2 (ja) | 心筋梗塞及び／又は狭心症のリスクを判定する方法 | |
| JP7165098B2 (ja) | 動脈硬化のリスクを判定する方法 | |
| JP7137525B2 (ja) | 接触性皮膚炎のリスクを判定する方法 | |
| JP7140707B2 (ja) | 緑内障のリスクを判定する方法 | |
| JP7161442B2 (ja) | リウマチのリスクを判定する方法 | |
| JP7161441B2 (ja) | 慢性副鼻腔炎のリスクを判定する方法 | |
| JP7165100B2 (ja) | 心房細動及び／又は心室細動のリスクを判定する方法 | |
| JP7138077B2 (ja) | 卵巣がん及び／又は子宮がんのリスクを判定する方法 | |
| JP7137523B2 (ja) | じんましんのリスクを判定する方法 | |
| JP7137526B2 (ja) | アトピー性皮膚炎のリスクを判定する方法 | |
| JP7137517B2 (ja) | 鉄欠乏性貧血のリスクを判定する方法 | |
| JP7137519B2 (ja) | 結核のリスクを判定する方法 | |
| JP7137522B2 (ja) | 脊椎側弯症のリスクを判定する方法 | |
| JP7106490B2 (ja) | 胆石のリスクを判定する方法 | |
| JP7138075B2 (ja) | 甲状腺機能低下症のリスクを判定する方法 | |
| JP7108574B2 (ja) | アレルギー性結膜炎のリスクを判定する方法 | |
| JP7165618B2 (ja) | アレルギー性鼻炎のリスクを判定する方法 | |
| JP7106489B2 (ja) | 脂肪肝のリスクを判定する方法 | |
| JP7137524B2 (ja) | 変形性膝関節症のリスクを判定する方法 | |
| JP7165619B2 (ja) | 慢性気管支炎のリスクを判定する方法 | |
| JP7137520B2 (ja) | 膵炎のリスクを判定する方法 | |
| JP7138073B2 (ja) | 注意欠陥多動性症候群のリスクを判定する方法 | |
| JP7108572B2 (ja) | 過食症のリスクを判定する方法 | |
| JP7137518B2 (ja) | 甲状腺機能亢進症のリスクを判定する方法 | |
| JP7137521B2 (ja) | 乾癬のリスクを判定する方法 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20200609 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20220111 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20220304 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20220617 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20220728 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20220819 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20220905 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 7138077 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |